New bladder cancer data are food for thought, but are not conclusive proof that urologists are over-treating early-stage bladder cancer and running up costs.
Their study found that in regions where patients receive costly, high-intensity surveillance and treatment, outcomes seem to be no better than in areas where monitoring and treatment are less intensive (see, "Regional expenditures for early-stage bladder Ca vary," page 1).
These data are important in providing checks and balances to help ensure that urologists are providing appropriate care and not over-utilizing limited health care dollars-an issue that's particularly germane to the national debate over health care reform. However, the study's findings need to be interpreted carefully, and the following points need to be considered:
Badrinath Konety, MD
Dr. Konety is associate professor and vice chair, urology and associate professor, epidemiology & biostatistics, University of California, San Francisco.
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.